Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Sell
32
VRDN Quote, Financials, Valuation and Earnings
Last price:
$13.18
Seasonality move
:
0.58%
Day range:
$13.09 - $13.50
52-week range:
$9.90 - $27.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,041.05x
P/B ratio:
2.28x
Volume:
683.5K
Avg. volume:
988.9K
1-year change:
5.05%
Market cap:
$1.1B
Revenue:
$302K
EPS (TTM):
-$3.77
Analysts' Opinion
-
Consensus RatingViridian Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.69, Viridian Therapeutics has an estimated upside of 193.33% from its current price of $13.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $13.53.
Fair Value
-
According to the consensus of 12 analysts, Viridian Therapeutics has 193.33% upside to fair value with a price target of $39.69 per share.
VRDN vs. S&P 500
-
Over the past 5 trading days, Viridian Therapeutics has overperformed the S&P 500 by 0.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viridian Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viridian Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Viridian Therapeutics reported revenues of $72K.
Earnings Growth
-
Viridian Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Viridian Therapeutics reported earnings per share of -$0.81.
Enterprise value:
594.4M
EV / Invested capital:
--
Price / LTM sales:
3,041.05x
EV / EBIT:
--
EV / Revenue:
1,968.13x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-41.91%
Net Income Margin (TTM):
-89387.09%
Return On Equity:
-46.02%
Return On Invested Capital:
-44.47%
Operating Margin:
-121488.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.8M | $314K | $302K | $72K | $72K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$134.3M | -$254.5M | -$299M | -$71.5M | -$87.5M | |
| EBITDA | -$129.1M | -$235.4M | -$266.4M | -$65.8M | -$78.7M | |
| Diluted EPS | -$4.03 | -$5.32 | -$3.77 | -$1.35 | -$0.81 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $129.6M | $200.2M | $431.2M | $486.5M | $738.5M | |
| Total Assets | $131.3M | $203.7M | $435.1M | $490.4M | $742.4M | |
| Current Liabilities | $10.7M | $13.6M | $33.3M | $26.6M | $47.9M | |
| Total Liabilities | $11.2M | $16M | $40M | $48.4M | $70.8M | |
| Total Equity | $120M | $187.7M | $395.1M | $442M | $671.6M | |
| Total Debt | -- | -- | $4.6M | $20.2M | $20.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$93.8M | -$184.2M | -$232.3M | -$38M | -$73.3M | |
| Cash From Investing | -$115.1M | -$94.3M | -$228.7M | -$169.7M | -$62.9M | |
| Cash From Financing | $322.2M | $225.7M | $457.7M | $198.9M | $35.5M | |
| Free Cash Flow | -$94.6M | -$185.1M | -$232.8M | -$38M | -$73.4M | |
VRDN
Sector
Market Cap
$1.1B
$34.4M
Price % of 52-Week High
49.74%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
-29.23%
-0.82%
1-Year Price Total Return
5.05%
-39.44%
Beta (5-Year)
0.857
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.35
200-day SMA
Sell
Level
$17.98
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$12.73
Relative Strength Index (RSI14)
Sell
Level
46.63
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-22.9299
50-day SMA
Sell
Level
$14.49
MACD (12, 26)
Sell
Level
-0.29
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.8186)
Sell
CA Score
(Annual)
Level (-0.5658)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.9618)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Stock Forecast FAQ
In the current month, VRDN has received 10 Buy ratings 2 Hold ratings, and 0 Sell ratings. The VRDN average analyst price target in the past 3 months is $39.69.
-
Where Will Viridian Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viridian Therapeutics share price will rise to $39.69 per share over the next 12 months.
-
What Do Analysts Say About Viridian Therapeutics?
Analysts are divided on their view about Viridian Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viridian Therapeutics is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Viridian Therapeutics's Price Target?
The price target for Viridian Therapeutics over the next 1-year time period is forecast to be $39.69 according to 12 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VRDN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viridian Therapeutics is a Buy. 10 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRDN?
You can purchase shares of Viridian Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viridian Therapeutics shares.
-
What Is The Viridian Therapeutics Share Price Today?
Viridian Therapeutics was last trading at $13.18 per share. This represents the most recent stock quote for Viridian Therapeutics. Yesterday, Viridian Therapeutics closed at $13.53 per share.
-
How To Buy Viridian Therapeutics Stock Online?
In order to purchase Viridian Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
